Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14007241 | 0.90 | EPHX2 (0.65) | EPHX2CYP2C9CYP2C19 | |
| SCHEMBL14541712 | 0.86 | EPHX2 (0.58) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL14007269 | 0.86 | EPHX2 (0.61) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL14007267 | 0.82 | EPHX2 (0.61) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL14007272 | 0.82 | EPHX2 (0.56) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL14007263 | 0.81 | EPHX2 (0.55) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL14007266 | 0.80 | EPHX2 (0.83) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL14007268 | 0.79 | EPHX2 (0.66) | EPHX2CYP2C9CYP2C19CYP2J2ALOX5 | |
| SCHEMBL14007270 | 0.79 | EPHX2 (0.73) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL14007265 | 0.78 | EPHX2 (0.48) | EPHX2CYP2C9CYP2C19CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280904-A1 | N-Substituted Pyridinone or Pyrimidinone Compounds Useful as Soluble Epoxide Hydrolase Inhibitors | ELDRUP ANNE BETTINA | 2008-11-13 | — | — | US | disclosed |
| US-20080280904-A1 | N-Substituted Pyridinone or Pyrimidinone Compounds Useful as Soluble Epoxide Hydrolase Inhibitors | ELDRUP ANNE BETTINA | 2008-11-13 | — | — | US | disclosed |
| WO-2007044491-A1 | N-SUBSTITUTED PYRIDINONE OR PYRIMIDINONE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280904-A1 | N-Substituted Pyridinone or Pyrimidinone Compounds Useful as Soluble Epoxide Hydrolase Inhibitors | EPHX1, EPHX2, DOHH | EPHX2 2/4885CYP2C9 238/4885CYP2C19 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.